TRxADE HEALTH, Inc.

MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDS stands at 13.3M. In comparison, ONC has a market cap of 31.9B. Regarding current trading prices, MEDS is priced at $7.59, while ONC trades at $298.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDS currently has a P/E ratio of -0.31, whereas ONC's P/E ratio is 121.01. In terms of profitability, MEDS's ROE is -2.36%, compared to ONC's ROE of +0.07%. Regarding short-term risk, MEDS is more volatile compared to ONC. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check ONC's competition here

MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDS stands at 13.3M. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, MEDS is priced at $7.59, while WBA trades at $11.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDS currently has a P/E ratio of -0.31, whereas WBA's P/E ratio is -1.64. In terms of profitability, MEDS's ROE is -2.36%, compared to WBA's ROE of -0.39%. Regarding short-term risk, MEDS is more volatile compared to WBA. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check WBA's competition here

MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDS stands at 13.3M. In comparison, DMRA has a market cap of 1.5B. Regarding current trading prices, MEDS is priced at $7.59, while DMRA trades at $25.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDS currently has a P/E ratio of -0.31, whereas DMRA's P/E ratio is -6.41. In terms of profitability, MEDS's ROE is -2.36%, compared to DMRA's ROE of -3.12%. Regarding short-term risk, MEDS is more volatile compared to DMRA. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check DMRA's competition here

MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDS stands at 13.3M. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, MEDS is priced at $7.59, while HROWL trades at $25.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDS currently has a P/E ratio of -0.31, whereas HROWL's P/E ratio is N/A. In terms of profitability, MEDS's ROE is -2.36%, compared to HROWL's ROE of -0.10%. Regarding short-term risk, MEDS is more volatile compared to HROWL. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check HROWL's competition here

MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDS stands at 13.3M. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, MEDS is priced at $7.59, while HROWM trades at $26.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDS currently has a P/E ratio of -0.31, whereas HROWM's P/E ratio is N/A. In terms of profitability, MEDS's ROE is -2.36%, compared to HROWM's ROE of -0.10%. Regarding short-term risk, MEDS is more volatile compared to HROWM. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check HROWM's competition here

MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDS stands at 13.3M. In comparison, ATAI has a market cap of 816.7M. Regarding current trading prices, MEDS is priced at $7.59, while ATAI trades at $4.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDS currently has a P/E ratio of -0.31, whereas ATAI's P/E ratio is -1.49. In terms of profitability, MEDS's ROE is -2.36%, compared to ATAI's ROE of -3.90%. Regarding short-term risk, MEDS is less volatile compared to ATAI. This indicates potentially lower risk in terms of short-term price fluctuations for MEDS.Check ATAI's competition here

MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDS stands at 13.3M. In comparison, CGEM has a market cap of 802M. Regarding current trading prices, MEDS is priced at $7.59, while CGEM trades at $13.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDS currently has a P/E ratio of -0.31, whereas CGEM's P/E ratio is -3.94. In terms of profitability, MEDS's ROE is -2.36%, compared to CGEM's ROE of -0.46%. Regarding short-term risk, MEDS is more volatile compared to CGEM. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check CGEM's competition here

MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDS stands at 13.3M. In comparison, HITI has a market cap of 224.6M. Regarding current trading prices, MEDS is priced at $7.59, while HITI trades at $2.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDS currently has a P/E ratio of -0.31, whereas HITI's P/E ratio is -6.08. In terms of profitability, MEDS's ROE is -2.36%, compared to HITI's ROE of -0.41%. Regarding short-term risk, MEDS is more volatile compared to HITI. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check HITI's competition here

MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDS stands at 13.3M. In comparison, LFMD has a market cap of 218.8M. Regarding current trading prices, MEDS is priced at $7.59, while LFMD trades at $4.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDS currently has a P/E ratio of -0.31, whereas LFMD's P/E ratio is -15.20. In terms of profitability, MEDS's ROE is -2.36%, compared to LFMD's ROE of -1.18%. Regarding short-term risk, MEDS is more volatile compared to LFMD. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check LFMD's competition here

MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDS stands at 13.3M. In comparison, LFMDP has a market cap of 161.9M. Regarding current trading prices, MEDS is priced at $7.59, while LFMDP trades at $23.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDS currently has a P/E ratio of -0.31, whereas LFMDP's P/E ratio is -10.53. In terms of profitability, MEDS's ROE is -2.36%, compared to LFMDP's ROE of -1.18%. Regarding short-term risk, MEDS is more volatile compared to LFMDP. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check LFMDP's competition here

MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDS stands at 13.3M. In comparison, LFLY has a market cap of 114.9M. Regarding current trading prices, MEDS is priced at $7.59, while LFLY trades at $37.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDS currently has a P/E ratio of -0.31, whereas LFLY's P/E ratio is -0.04. In terms of profitability, MEDS's ROE is -2.36%, compared to LFLY's ROE of +0.17%. Regarding short-term risk, MEDS is less volatile compared to LFLY. This indicates potentially lower risk in terms of short-term price fluctuations for MEDS.Check LFLY's competition here

MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDS stands at 13.3M. In comparison, YI has a market cap of 58.3M. Regarding current trading prices, MEDS is priced at $7.59, while YI trades at $6.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDS currently has a P/E ratio of -0.31, whereas YI's P/E ratio is -0.30. In terms of profitability, MEDS's ROE is -2.36%, compared to YI's ROE of +0.08%. Regarding short-term risk, MEDS is more volatile compared to YI. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check YI's competition here

MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDS stands at 13.3M. In comparison, PETS has a market cap of 49.2M. Regarding current trading prices, MEDS is priced at $7.59, while PETS trades at $2.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDS currently has a P/E ratio of -0.31, whereas PETS's P/E ratio is -0.74. In terms of profitability, MEDS's ROE is -2.36%, compared to PETS's ROE of -1.22%. Regarding short-term risk, MEDS is more volatile compared to PETS. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check PETS's competition here

MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDS stands at 13.3M. In comparison, RNTX has a market cap of 42.1M. Regarding current trading prices, MEDS is priced at $7.59, while RNTX trades at $1.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDS currently has a P/E ratio of -0.31, whereas RNTX's P/E ratio is -0.77. In terms of profitability, MEDS's ROE is -2.36%, compared to RNTX's ROE of -2.81%. Regarding short-term risk, MEDS is less volatile compared to RNTX. This indicates potentially lower risk in terms of short-term price fluctuations for MEDS.Check RNTX's competition here

MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDS stands at 13.3M. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, MEDS is priced at $7.59, while RAD trades at $0.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDS currently has a P/E ratio of -0.31, whereas RAD's P/E ratio is -0.05. In terms of profitability, MEDS's ROE is -2.36%, compared to RAD's ROE of +2.76%. Regarding short-term risk, MEDS is less volatile compared to RAD. This indicates potentially lower risk in terms of short-term price fluctuations for MEDS.Check RAD's competition here

MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDS stands at 13.3M. In comparison, SDEV has a market cap of 35M. Regarding current trading prices, MEDS is priced at $7.59, while SDEV trades at $1.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDS currently has a P/E ratio of -0.31, whereas SDEV's P/E ratio is -0.23. In terms of profitability, MEDS's ROE is -2.36%, compared to SDEV's ROE of +12.37%. Regarding short-term risk, MEDS is more volatile compared to SDEV. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check SDEV's competition here

MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDS stands at 13.3M. In comparison, POM has a market cap of 34.2M. Regarding current trading prices, MEDS is priced at $7.59, while POM trades at $0.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDS currently has a P/E ratio of -0.31, whereas POM's P/E ratio is -6.40. In terms of profitability, MEDS's ROE is -2.36%, compared to POM's ROE of +0.07%. Regarding short-term risk, MEDS is less volatile compared to POM. This indicates potentially lower risk in terms of short-term price fluctuations for MEDS.Check POM's competition here

MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDS stands at 13.3M. In comparison, KYNB has a market cap of 28.4M. Regarding current trading prices, MEDS is priced at $7.59, while KYNB trades at $7.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDS currently has a P/E ratio of -0.31, whereas KYNB's P/E ratio is -0.49. In terms of profitability, MEDS's ROE is -2.36%, compared to KYNB's ROE of -1.62%. Regarding short-term risk, MEDS is more volatile compared to KYNB. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check KYNB's competition here

MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDS stands at 13.3M. In comparison, NEUP has a market cap of 27.9M. Regarding current trading prices, MEDS is priced at $7.59, while NEUP trades at $5.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDS currently has a P/E ratio of -0.31, whereas NEUP's P/E ratio is -7.49. In terms of profitability, MEDS's ROE is -2.36%, compared to NEUP's ROE of -15.38%. Regarding short-term risk, MEDS is more volatile compared to NEUP. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check NEUP's competition here

MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDS stands at 13.3M. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, MEDS is priced at $7.59, while CJJD trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDS currently has a P/E ratio of -0.31, whereas CJJD's P/E ratio is -0.46. In terms of profitability, MEDS's ROE is -2.36%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, MEDS is more volatile compared to CJJD. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check CJJD's competition here

MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDS stands at 13.3M. In comparison, MSLE has a market cap of 9.2M. Regarding current trading prices, MEDS is priced at $7.59, while MSLE trades at $7.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDS currently has a P/E ratio of -0.31, whereas MSLE's P/E ratio is -4.21. In terms of profitability, MEDS's ROE is -2.36%, compared to MSLE's ROE of -0.52%. Regarding short-term risk, MEDS is more volatile compared to MSLE. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check MSLE's competition here

MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDS stands at 13.3M. In comparison, AIXC has a market cap of 7.9M. Regarding current trading prices, MEDS is priced at $7.59, while AIXC trades at $1.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDS currently has a P/E ratio of -0.31, whereas AIXC's P/E ratio is -0.19. In terms of profitability, MEDS's ROE is -2.36%, compared to AIXC's ROE of -1.05%. Regarding short-term risk, MEDS is more volatile compared to AIXC. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check AIXC's competition here

MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDS stands at 13.3M. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, MEDS is priced at $7.59, while SSY trades at $1.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDS currently has a P/E ratio of -0.31, whereas SSY's P/E ratio is -2.86. In terms of profitability, MEDS's ROE is -2.36%, compared to SSY's ROE of -0.15%. Regarding short-term risk, MEDS is less volatile compared to SSY. This indicates potentially lower risk in terms of short-term price fluctuations for MEDS.Check SSY's competition here

MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDS stands at 13.3M. In comparison, HKPD has a market cap of 7.3M. Regarding current trading prices, MEDS is priced at $7.59, while HKPD trades at $0.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDS currently has a P/E ratio of -0.31, whereas HKPD's P/E ratio is -11.01. In terms of profitability, MEDS's ROE is -2.36%, compared to HKPD's ROE of -0.01%. Regarding short-term risk, MEDS is more volatile compared to HKPD. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check HKPD's competition here

MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDS stands at 13.3M. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, MEDS is priced at $7.59, while MDVL trades at $1.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDS currently has a P/E ratio of -0.31, whereas MDVL's P/E ratio is -0.05. In terms of profitability, MEDS's ROE is -2.36%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, MEDS is less volatile compared to MDVL. This indicates potentially lower risk in terms of short-term price fluctuations for MEDS.Check MDVL's competition here

MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDS stands at 13.3M. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, MEDS is priced at $7.59, while ATNFW trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDS currently has a P/E ratio of -0.31, whereas ATNFW's P/E ratio is N/A. In terms of profitability, MEDS's ROE is -2.36%, compared to ATNFW's ROE of -0.91%. Regarding short-term risk, MEDS is less volatile compared to ATNFW. This indicates potentially lower risk in terms of short-term price fluctuations for MEDS.Check ATNFW's competition here

MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDS stands at 13.3M. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, MEDS is priced at $7.59, while BGMSP trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDS currently has a P/E ratio of -0.31, whereas BGMSP's P/E ratio is N/A. In terms of profitability, MEDS's ROE is -2.36%, compared to BGMSP's ROE of -2.95%. Regarding short-term risk, MEDS is more volatile compared to BGMSP. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check BGMSP's competition here

MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDS stands at 13.3M. In comparison, BGMS has a market cap of 2.1M. Regarding current trading prices, MEDS is priced at $7.59, while BGMS trades at $0.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDS currently has a P/E ratio of -0.31, whereas BGMS's P/E ratio is -0.15. In terms of profitability, MEDS's ROE is -2.36%, compared to BGMS's ROE of -0.58%. Regarding short-term risk, MEDS is more volatile compared to BGMS. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check BGMS's competition here

MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDS stands at 13.3M. In comparison, NVOH has a market cap of 2M. Regarding current trading prices, MEDS is priced at $7.59, while NVOH trades at $22.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDS currently has a P/E ratio of -0.31, whereas NVOH's P/E ratio is 11.89. In terms of profitability, MEDS's ROE is -2.36%, compared to NVOH's ROE of +0.00%. Regarding short-term risk, MEDS is more volatile compared to NVOH. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check NVOH's competition here

MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDS stands at 13.3M. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, MEDS is priced at $7.59, while AZNH trades at $53.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDS currently has a P/E ratio of -0.31, whereas AZNH's P/E ratio is 38.35. In terms of profitability, MEDS's ROE is -2.36%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, MEDS is more volatile compared to AZNH. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check AZNH's competition here

MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDS stands at 13.3M. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, MEDS is priced at $7.59, while LFLYW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDS currently has a P/E ratio of -0.31, whereas LFLYW's P/E ratio is -0.04. In terms of profitability, MEDS's ROE is -2.36%, compared to LFLYW's ROE of +0.17%. Regarding short-term risk, MEDS is more volatile compared to LFLYW. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check LFLYW's competition here

MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDS stands at 13.3M. In comparison, BIMI has a market cap of 1.2K. Regarding current trading prices, MEDS is priced at $7.59, while BIMI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDS currently has a P/E ratio of -0.31, whereas BIMI's P/E ratio is N/A. In terms of profitability, MEDS's ROE is -2.36%, compared to BIMI's ROE of -2.94%. Regarding short-term risk, MEDS is more volatile compared to BIMI. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check BIMI's competition here

MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDS stands at 13.3M. In comparison, OREX has a market cap of 0. Regarding current trading prices, MEDS is priced at $7.59, while OREX trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDS currently has a P/E ratio of -0.31, whereas OREX's P/E ratio is N/A. In terms of profitability, MEDS's ROE is -2.36%, compared to OREX's ROE of -0.54%. Regarding short-term risk, MEDS is less volatile compared to OREX. This indicates potentially lower risk in terms of short-term price fluctuations for MEDS.Check OREX's competition here

MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDS stands at 13.3M. In comparison, CPD has a market cap of 0. Regarding current trading prices, MEDS is priced at $7.59, while CPD trades at $5.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDS currently has a P/E ratio of -0.31, whereas CPD's P/E ratio is N/A. In terms of profitability, MEDS's ROE is -2.36%, compared to CPD's ROE of N/A. Regarding short-term risk, MEDS is more volatile compared to CPD. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check CPD's competition here

MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDS stands at 13.3M. In comparison, POZN has a market cap of 0. Regarding current trading prices, MEDS is priced at $7.59, while POZN trades at $5.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDS currently has a P/E ratio of -0.31, whereas POZN's P/E ratio is N/A. In terms of profitability, MEDS's ROE is -2.36%, compared to POZN's ROE of +0.61%. Regarding short-term risk, MEDS is less volatile compared to POZN. This indicates potentially lower risk in terms of short-term price fluctuations for MEDS.Check POZN's competition here

MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDS stands at 13.3M. In comparison, SHPG has a market cap of 0. Regarding current trading prices, MEDS is priced at $7.59, while SHPG trades at $179.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDS currently has a P/E ratio of -0.31, whereas SHPG's P/E ratio is N/A. In terms of profitability, MEDS's ROE is -2.36%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, MEDS is more volatile compared to SHPG. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check SHPG's competition here

MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDS stands at 13.3M. In comparison, IPXL has a market cap of 0. Regarding current trading prices, MEDS is priced at $7.59, while IPXL trades at $18.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDS currently has a P/E ratio of -0.31, whereas IPXL's P/E ratio is N/A. In terms of profitability, MEDS's ROE is -2.36%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, MEDS is more volatile compared to IPXL. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check IPXL's competition here

MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDS stands at 13.3M. In comparison, ESRX has a market cap of 0. Regarding current trading prices, MEDS is priced at $7.59, while ESRX trades at $92.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDS currently has a P/E ratio of -0.31, whereas ESRX's P/E ratio is N/A. In terms of profitability, MEDS's ROE is -2.36%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, MEDS is more volatile compared to ESRX. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check ESRX's competition here